Ketanserin is a biologic acclimated clinically as an antihypertensive abettor and in accurate analysis to abstraction the serotonin system; specifically, the 5-HT2 receptor family. It was apparent at Janssen Pharmaceutica in 1980.
It is classified as an antihypertensive by the World Health Organization and the National Institute of Health.
It has been acclimated to about-face pulmonary hypertension acquired by protamine (which in about-face was administered to about-face the furnishings of heparin overdose).
The abridgement in hypertension is not associated with reflex tachycardia.
It has been acclimated in cardiac surgery.